Record CStone Funding Heralds New Era For China Startups

With $150m in hand and a pipeline covering five therapeutic areas, CStone has already broken the record for the largest Series A investment in a Chinese biopharma startup. If that's not impressive enough, add a CEO from big pharma and support from China’s largest CRO.

Founded in Shanghai and Suzhou, CStone PharmaceuticalsCo. Ltd is not your normal Chinese biopharma startup – it seems to have all the ingredients for success, all come together, in no time.

In a July 4 announcement of a Series A financing, CStone said it had raised $150m, appointed a new chief executive, and is progressing a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia